Archive
422 releases
Revenue growth of 27% driven by strong performance in molecular profiling services, including approximately 61,500 clinical cases, consisting of over…
Q3 Net Revenue Increased 257% to $298.7 Million
Transaction Expands Company's Operations Along Growing Interstate 85 Corridor DOTHAN, Ala., Nov. 4, 2026 — Construction Partners, Inc. (NASDAQ: ROAD)…
Third Quarter Results Reflect Sequential Earnings Improvement Amid Continued Market Challenges; Goodyear Advancing Next Phase of Transformation Third…
Raises FY 2026 Sales and Adjusted EPS Outlook on Continued Strong Demand Across Its Diversified End Markets
PAPZIMEOS® net revenue rose 37% quarter-over-quarter to $72.9 million in the third quarter of 2026 bringing launch-to-date net product revenue to…
VAX-31 Adult Indication: Announced Positive Topline Data from OPUS-1 Pivotal Phase 3 Trial; VAX-31 Met All Prespecified Primary Endpoints, Was Well…
FS Credit Opportunities Corp. (NYSE: FSCO) today announced that it will release its financial results for the third quarter ended September 30, 2026,…
– Delivered 51% Net Sales Growth –
Conference Call to Begin Today at 4:30 p.m. ET
Received Regenerative Medicine Advanced Therapy (RMAT) Designation from U.S. FDA for TN-401 Gene Therapy for PKP2-Associated Arrhythmogenic Right…
AppLovin posted record third quarter earnings: net income grew 72% year-over-year to $1.44 billion on record revenue of $2.18 billion, up 55%…
PTC (NASDAQ: PTC) today reported financial results for its fourth fiscal quarter and full fiscal year ended September 30, 2026. Fourth Fiscal Quarter…
Ribupatide oral global Phase 3 program expected to begin in 1H 2027 following completion of End-of-Phase 2 meeting with FDA
